A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

Phase 1

Completed

• Conditions: Severe Acute Respiratory Syndrome; Coronavirus; SARS-CoV-2; COVID-19
• Interventions: Biological: CVnCoV Vaccine; Drug: Placebo

• Registration Number: NCT04449276
• Lead Sponsor: CureVac

Brief Summary

This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of CVnCoV at different dose levels.

Detailed Description

Funded by Coalition for Epidemic Preparedness Innovations (CEPI).

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

Study Timeline

• Study Start: 2020-06-18
• Study First Submitted: 2020-06-18
• Study First Submitted QC: 2020-06-23
• Study First Posted: 2020-06-26
• Primary Completion: 2021-12-21
• Study Completion: 2021-12-21
• Status Verified: 2022-04
• Results First Submitted: 2022-04-29
• Results First Submitted QC: 2022-04-29
• Last Update Submitted: 2022-04-29
• Results First Posted: 2023-01-30
• Last Update Posted: 2023-01-30

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 280

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

The following criterion applies to all open-label sentinel participants:

• Participants with SARS-CoV-2 positive serology as confirmed by testing at enrollment.

The following criteria apply to all participants, except those with SARS-CoV-2 positive serology:

• Participants considered at the Investigator's discretion to be at increased risk to acquire COVID-19 disease (including, but not limited to, health care workers with direct involvement in patient care or care of long-term care recipients).
• History of confirmed COVID-19 disease or known exposure to an individual with confirmed COVID-19 disease or SARS-CoV-2 infection within the past 2 weeks.

The following criteria apply to all participants:

• Use of any investigational or non-registered product (vaccine or drug) other than the trial vaccine within 28 days preceding the administration of the trial vaccine, or planned use during the trial period.

• Receipt of any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrollment in this trial or planned receipt of any vaccine within 28 days of trial vaccine administration.

• Receipt of any investigational SARS-CoV-2 or other CoV vaccine prior to the administration of the trial vaccine.

• Any treatment with immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the trial vaccine or planned use during the trial, with the exception of topically-applied steroids. Corticosteroids used in the context of COVID-19 disease of participants with SARS CoV 2 positive serology are not exclusionary.

• Any medically diagnosed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination, including known human immunodeficiency virus infection, hepatitis B virus infection and hepatitis C virus infection.

• History of a pIMD (potential immune-mediated disease).

• History of angioedema.

• Any known allergy, including allergy to any component of CVnCoV or aminoglycoside antibiotics. A history of hay fever or seasonal allergies (pollinosis) that does not require current treatment (e.g., anti-histamines) during the vaccination period (1 month before first vaccination until 1 month after last vaccination) is not exclusionary.

• History of or current alcohol and/or drug abuse.

• Participants who are active smokers, were active smokers within the last year (including any vaping in the last year) or have a total smoking history ≥10 pack years.

• Active or currently active SARS-CoV-2 infection as confirmed by reactive PCR within 3 days of first trial vaccine administration.

• History of confirmed SARS or MERS

• Administration of immunoglobulins (Igs) and/or any blood products within the 3 months preceding the administration of any dose of the trial vaccine.

• Presence or evidence of significant acute or chronic, medical or psychiatric illness. Significant medical or psychiatric illnesses include but are not limited to:

  • Respiratory disease (e.g., chronic obstructive pulmonary disease [COPD], asthma) requiring daily medications currently or any treatment of respiratory disease exacerbations (e.g., asthma exacerbation) in the last 5 years.
  • Respiratory disease with clinically significant dyspnea in the last 5 years (except COVID-19 disease in participants with SARS-CoV-2 positive serology).
  • Asthma medications: inhaled, oral, or intravenous (IV) corticosteroids, leukotriene modifiers, long- and short-acting beta agonists, theophylline, ipratropium, biologics.
  • Significant cardiovascular disease (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease, history of stroke, peripheral artery disease, pulmonary embolism) or history of myocarditis or pericarditis as an adult.
  • Elevated blood pressure or hypertension, even if well-controlled.
  • Diabetes mellitus type 1 or 2.
  • History of any neurological disorders or seizures including Guillain-Barré syndrome, with the exception of febrile seizures during childhood.
  • Current or past malignancy, unless completely resolved without sequelae for >5 years.

• Foreseeable non-compliance with protocol as judged by the Investigator.

• For females: pregnancy or lactation.

• History of any anaphylactic reactions.

• Participants with impaired coagulation or any bleeding disorder in whom an IM injection or a blood draw is contraindicated.

• Participants employed by the Sponsor, Investigator or trial site, or relatives of research staff working on this trial.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Dose Escalation CVnCoV	CVnCoV Vaccine	Participants will be vaccinated with CVnCoV at escalating dose levels on Day 1 and Day 29. Safety data will inform the decision to continue enrolling at the current dose level, or to proceed to dose escalation. Initially, dose levels of 2, 4 and 8 μg will be evaluated. Dose levels of 2, 4, 6, 8 and 12µg will be evaluated with potential increase to dose levels up to 20 μg.
Dose Escalation Placebo	Placebo	Participants will be given placebo on Day 1 and Day 29.

Primary Outcome Measures

Name	Time	Method
Number of Participants With Grade 3 Adverse Reactions or Any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 60 Hours After the First Vaccination	Up to 60 hours after vaccination on Day 1	Grade 3 refers to the highest grading on the FDA toxicity scale where a higher grade indicates a worse outcome. An SAE was defined as any untoward medical occurrence that, at any dose: * Resulted in death.; * Was life-threatening.; * Required inpatient hospitalization or prolongation of existing hospitalization.; * Resulted in persistent disability/incapacity.; * Was a congenital anomaly/birth defect in the offspring of the participant.; * Was an important medical event.
Number of Participants With Solicited Local Adverse Events	Up to 7 days after vaccination (Days 1 to 8 and Day 29 to 36)	Reactogenicity was assessed daily via collection of solicited local AEs (injection site pain, redness, swelling, and itching) using paper diary cards.
Intensity of Solicited Local Adverse Events Per the FDA Toxicity Grading Scale	Up to 7 days after vaccination (Days 1 to 8 and Days 29 to 36)	Reactogenicity was assessed daily via collection of solicited local AEs (injection site pain, redness, swelling, and itching) using paper diary cards. Intensity of solicited local AEs and solicited systemic AEs were graded per the FDA Toxicity Grading Scale at Grades 1-3, where higher grades indicate a worse outcome.
Duration of Solicited Local Adverse Events	Up to 7 days after vaccination (Days 1 to 8 and Days 29 to 36)	Reactogenicity was assessed daily via collection of solicited local AEs (injection site pain, redness, swelling, and itching) using paper diary cards. Duration was calculated as consecutive days with a respective solicited AE regardless of the grade of the AE.
Number of Participants With Solicited Systemic Adverse Events	Up to 7 days after vaccination (Days 1 to 8 and Days 29 to 36)	Reactogenicity was assessed daily via collection of solicited systemic AEs (fever, headache, fatigue, chills, myalgia, arthralgia, nausea/vomiting, and diarrhea) using paper diary cards.
Intensity of Solicited Systemic Adverse Events Per the FDA Toxicity Grading Scale	Up to 7 days after vaccination (Days 1 to 8 and Days 29 to 36)	Reactogenicity was assessed daily via collection of solicited systemic AEs (fever, headache, fatigue, chills, myalgia, arthralgia, nausea/vomiting, and diarrhea) using paper diary cards. Intensity of solicited local AEs and solicited systemic AEs were graded per the FDA Toxicity Grading Scale at Grades 1-3, where higher grades indicate a worse outcome.
Duration of Solicited Systemic Adverse Events	Up to 7 days after vaccination (Days 1 to 8 and Days 29 to 36)	Reactogenicity was assessed daily via collection of solicited systemic AEs (fever, headache, fatigue, chills, myalgia, arthralgia, nausea/vomiting, and diarrhea) using paper diary cards. Duration was calculated as consecutive days with a respective solicited AE regardless of the grade of the AE.
Number of Participants With Solicited Systemic Adverse Events Considered Related to Trial Vaccine	Up to 7 days after vaccination (Days 1 to 8 and Days 29 to 36)	Reactogenicity was assessed daily via collection of solicited systemic AEs (fever, headache, fatigue, chills, myalgia, arthralgia, nausea/vomiting, and diarrhea) using paper diary cards. The Investigator assessed the relationship between trial vaccine and each occurrence of each AE.
Number of Participants With Grade 3 Adverse Reactions or Any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 24 Hours After the First Vaccination	Up to 24 hours after vaccination on Day 1	Grade 3 refers to the highest grading on the FDA toxicity scale where a higher grade indicates a worse outcome. An SAE was defined as any untoward medical occurrence that, at any dose: * Resulted in death.; * Was life-threatening.; * Required inpatient hospitalization or prolongation of existing hospitalization.; * Resulted in persistent disability/incapacity.; * Was a congenital anomaly/birth defect in the offspring of the participant.; * Was an important medical event.
Number of Participants With Unsolicited Adverse Events	Up to 28 days after vaccination (Days 1 to 29 and Days 29 to 57)	Diaries were used for collection of unsolicited AEs on each vaccination day and the following 28 days. In addition, participants were contacted by phone to verify whether they had any health concerns since the last visit.
Intensity of Unsolicited Adverse Events Assessed by the Investigator	Up to 28 days after vaccination (Days 1 to 29 and Days 29 to 57)	Diaries were used for collection of unsolicited AEs on each vaccination day and the following 28 days. In addition, participants were contacted by phone to verify whether they had any health concerns since the last visit. Participants were included only once, at the maximum severity. The Investigator made an assessment of intensity for each AE reported during the trial and assigned it to one of the following categories: * Mild: an event that was easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities.; * Moderate: an event that caused sufficient discomfort to interfere with normal everyday activities.; * Severe: an event that prevented normal everyday activities.
Number of Participants With Unsolicited Adverse Events Considered Related to Trial Vaccine	Up to 28 days after vaccination (Days 1 to 29 and Days 29 to 57)	Diaries were used for collection of unsolicited AEs on each vaccination day and the following 28 days. In addition, participants were contacted by phone to verify whether they had any health concerns since the last visit. The Investigator assessed the relationship between trial vaccine and each occurrence of each AE.
Number of Participants With One or More Serious Adverse Events (SAEs)	Baseline to Day 393	An SAE was defined as any untoward medical occurrence that, at any dose: * Resulted in death.; * Was life-threatening.; * Required inpatient hospitalization or prolongation of existing hospitalization.; * Resulted in persistent disability/incapacity.; * Was a congenital anomaly/birth defect in the offspring of the participant.; * Was an important medical event.
Number of Participants With One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine	Baseline to Day 393	An SAE was defined as any untoward medical occurrence that, at any dose: * Resulted in death.; * Was life-threatening.; * Required inpatient hospitalization or prolongation of existing hospitalization.; * Resulted in persistent disability/incapacity.; * Was a congenital anomaly/birth defect in the offspring of the participant.; * Was an important medical event. The Investigator assessed the relationship between trial vaccine and each occurrence of each AE.
Number of Participants With One or More Adverse Events of Special Interest (AESIs)	Day 1 to Day 393	The following events will be considered as AESIs: adverse events with a suspected immune-mediated etiology, COVID-19 disease and other adverse events relevant to SARS-CoV vaccine development or the target disease.

Secondary Outcome Measures

Name	Time	Method
Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Antibodies	Day 8, Day 15, Day 29, Day 36, Day 43, Day 57, Day 120 and Day 211	Measured using Enzyme-Linked Immunosorbent Assay (ELISA). In participants who did not get exposed to SARS-CoV-2 before the trial or during the trial before the applicable sample was collected, as measured by ELISA to SARS-CoV-2 N-antigen, seroconversion is defined as an increase in titer in antibodies against SARS-CoV-2 spike protein versus baseline. In subjects seropositive for SARS-CoV-2 at baseline, seroconversion is defined as a 2-fold increase in titer in antibodies against SARS-CoV-2 spike protein versus baseline.
Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Antibodies	Day 8, Day 15, Day 29, Day 36, Day 43, Day 57, Day 120 and Day 211	Measured using Enzyme-Linked Immunosorbent Assay (ELISA).
Number of Participants Seroconverting for SARS-CoV-2 Spike Protein Receptor-Binding Domain (RBD) Antibodies	Day 8, Day 15, Day 29, Day 36, Day 43, Day 57, Day 120 and Day 211	Measured using Enzyme-Linked Immunosorbent Assay (ELISA). In participants who did not get exposed to SARS-CoV-2 before the trial or during the trial before the applicable sample was collected, as measured by ELISA to SARS-CoV-2 N-antigen, seroconversion is defined as an increase in titer in antibodies against SARS-CoV-2 spike RBD protein versus baseline. In subjects seropositive for SARS-CoV-2 at baseline, seroconversion is defined as a 2-fold increase in titer in antibodies against SARS-CoV-2 spike RBD protein versus baseline.
Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Spike Protein Receptor-Binding Domain (RBD) Antibodies	Day 8, Day 15, Day 29, Day 36, Day 43, Day 57, Day 120 and Day 211	Measured using Enzyme-Linked Immunosorbent Assay (ELISA).
Number of Participants Seroconverting for SARS-CoV-2 Neutralizing Antibodies	Day 8, Day 15, Day 29, Day 36, Day 43, Day 57, Day 120 and Day 211	Measured using an activity assay. In participants who did not get exposed to SARS-CoV-2 before the trial or during the trial before the applicable sample was collected, as measured by ELISA to SARS-CoV-2 N-antigen, seroconversion is defined as an increase in titer in SARS-CoV-2 neutralizing antibodies versus baseline. In participants seropositive for SARS-CoV-2 at baseline, seroconversion is defined as a 2-fold increase in titer in SARS-CoV-2 neutralizing antibodies versus baseline.
Geometric Mean Titers (GMTs) of Serum SARS-CoV-2 Neutralizing Antibodies	Day 8, Day 15, Day 29, Day 36, Day 43, Day 57, Day 120 and Day 211	Measured using an activity assay.

Trial Locations

Locations (4)

Universitair Ziekenhuis Ghent; 🇧🇪 Ghent, Belgium

Medical University Hannover (MHH); 🇩🇪 Hannover, Germany

University Hospital Tübingen Institut für Tropenmedizin; 🇩🇪 Tübingen, Germany

Ludwig-Maximilians-Universität München; 🇩🇪 München, Bavaria, Germany